
Latanoprost
Latanoprost is a prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antihypertensive agent, an antiglaucoma drug and a prodrug. It is a triol, an isopropyl ester and a prostaglandins Falpha. It is functionally related to a latanoprost free acid. — ChEBI
- Nom IUPAC
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
- Formule moléculaire
- C26H40O5
- Masse moléculaire
- 432.6 g/mol
- Masse exacte
- 432.28757437 Da
- XLogP3
- 4,3
- Surface polaire topologique
- 87,0 Ų
- Donneurs de liaisons hydrogène
- 3
- Accepteurs de liaisons hydrogène
- 5
- Unités covalentes
- 1
- Stéréocentres définis
- 5
Également connu sous le nom de
16 autres noms signalés
Identifiants de bases de données externes
- ChEBI:CHEBI:6384
- ChEMBL:CHEMBL1051
- EPA DTXSID:DTXSID1041057
- PubMed:29921209
- PubMed:25811541
- PubMed:25328381
- PubMed:23956101
- PubMed:20019365
- PubMed:19403113
- PubMed:18721251
- PubMed:18166407
- PubMed:17539800
- PubMed:17459480
- PubMed:17416939
- PubMed:17102001
Preuves issues de bases de données scientifiques complémentaires
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Boiling Point: 583.8 Source: DrugBank
- pKa: 4.88 Source: DrugBank
- LogP: 3.98 Source: DrugBank
- LogP: 4.4 Source: Human Metabolome Database (HMDB)
- Physical Description: Liquid Source: Human Metabolome Database (HMDB)
- Solubility: 1.29e-02 g/L Source: Human Metabolome Database (HMDB)
- Note: This chemical does not meet GHS hazard criteria for 0.7% (1 of 145) of reports. Source: European Chemicals Agency (ECHA)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H300 (63.4%): Fatal if swallowed [Danger Acute toxicity, oral]; H301 (11%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (62.1%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 145 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 1 of 145 reports by companies.; There are 15 notifications provided by 144 of 145 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Toxicity Summary: Researchers found no carcinogenesis or mutagenesis with latanoprost, and the drug did not affect fertility in animal studies. However, latanoprost was noted to cause a chromosomal aberration in treated human lymphocytes. Intravenous infusion of 3 μg/kg of latanoprost in healthy volunteers produced plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution, and researchers identified no ADR. There is no evidence to establish a correlation between latanoprost administration and ocular or cutaneous melanoma.; Intravenous infusion of 5.5 to 10 μg/kg resulted in fatigue, sweating, dizziness, nausea, and abdominal pain. According to the manufacturer's labeling, treatment should be symptomatic if there is an overdosage with latanoprost ophthalmic solution. Source: StatPearls
- Uses: Use (kg) in USA (2002): 1; Consumption (g per capita) in the USA (2002): 3.3e-06; Calculated removal (%): 100 Source: NORMAN Suspect List Exchange
Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source
Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.
Couverture des sources complémentaires et état des correspondances
| Source | Résultat | Vérifié |
|---|---|---|
| NIH PubChem PUG-View | Correspondance exacte | 2026-08-31 |
Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.
Récupéré depuis NIH PubChem le 2026-08-31 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.